YHLO × Sanofi — Building a Type 1 Diabetes Ecosystem Together
On November 6, 2025, during the 8th China International Import Expo, YHLO joined hands with Sanofi to launch the China Type 1 Diabetes Ecosystem Co-construction Alliance, marking a new step toward proactive diabetes prevention and management.
As the world’s first and only therapy proven to delay the onset of Type 1 diabetes, Sanofi’s Tzield® (teplizumab) has officially entered China. In this partnership, YHLO contributes its diagnostic innovation and technical expertise to enable early screening, accurate classification, and precise intervention for Type 1 diabetes.
YHLO’s comprehensive testing portfolio empowers full-pathway management:
🔹 Adiponectin – early Type 2 diabetes risk prediction (5–10 years in advance)
🔹 GADA, IAA, IA-2A, ICA, ZnT8A – autoantibody panel for Type 1 diabetes detection
🔹 C-peptide, Insulin – β-cell function evaluation
🔹 PIFI platform – digital intelligence for smarter monitoring
This collaboration represents a milestone in diabetes care, integrating “diagnosis + therapy” to bring precision and prevention together — and to let science better serve health.
Attachments:
Next Page
MORE NEWS
n November 18, 2025, YHLO’s 2025 Global Core Distributors Conference was successfully held in Düsseldorf, Germany. Under the theme “Academia-Driven, Shared Value,” the meeting brought together representatives from more than 30 core distributors worldwide. YHLO’s founder, Mr. Deming Hu, and Chairman, Mr. Kunhui Hu, led the company’s executive team to attend and discuss strategic development with partners.
2025-11-20
YHLO Secures Approval for the World’s First sCD146 CLIA Assay
YHLO has obtained approval from the Guangdong Medical Products Administration for its soluble CD146 (sCD146) CLIA assay, marking a major milestone in central nervous system (CNS) disease diagnostics. YHLO is now the first company worldwide to offer an sCD146 test for cerebrospinal fluid, bringing its total CLIA assay portfolio in China to 173.
2025-11-18
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
